RxDoctor Payments Data

Sandra Koehn, DO

Internal Medicine · Rochester, NYNPI 1184003568

Payments from drug & device makers

$2,457in general payments, 2019–2025

Across 151 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$512
  • AbbVie$443
  • Pfizer$372
  • GSK$224
  • Amarin Pharma, Inc.$188
  • AstraZeneca$177
  • plus $542 from 8 others

What the payments were for

  • Food & beverage$2,457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,457 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$13,571
Medicare patients
64
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$62,942
TrulicityDulaglutide45$57,385
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,733
OzempicSemaglutide30$33,284
JanuviaSitagliptin Phosphate16$23,017
JanumetSitagliptin Phos/Metformin Hcl14$21,211
RybelsusSemaglutide11$18,697
FarxigaDapagliflozin Propanediol12$15,773
Breo ElliptaFluticasone/Vilanterol15$10,048
Aripiprazole17$7,500
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$7,337
Atorvastatin Calcium475$6,581
Albuterol Sulfate HfaAlbuterol Sulfate81$3,448
Levothyroxine Sodium246$3,314
Gabapentin125$3,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$372$62,94259 claims
Lilly USA, LLCTrulicity$125$57,38545 claims
Novo NordiskOzempic, Rybelsus$512$51,98141 claims
GSKTrelegy Ellipta, Breo Ellipta$224$46,78049 claims
MerckJanuvia, Janumet$54$44,22830 claims
AstraZenecaFarxiga$177$15,77312 claims
AbbVieSynthroid$443$1,63123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →